Amedisys Inc (NASDAQ:AMED) hit a new 52-week high and low on Thursday . The stock traded as low as $83.56 and last traded at $83.52, with a volume of 4037 shares traded. The stock had previously closed at $82.23.
Several brokerages have weighed in on AMED. TheStreet upgraded Amedisys from a “c+” rating to an “a-” rating in a report on Monday, May 7th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Tuesday, March 6th. ValuEngine raised Amedisys from a “hold” rating to a “buy” rating in a research report on Tuesday, May 8th. Bank of America boosted their price target on Amedisys from $73.00 to $78.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 5th. Finally, BidaskClub raised Amedisys from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $70.55.
The stock has a market capitalization of $2.79 billion, a P/E ratio of 38.00, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.14.
In related news, major shareholder Kkr Credit Advisors (Us) Llc sold 2,437,424 shares of the company’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $73.96, for a total transaction of $180,271,879.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Michael Paul North sold 11,000 shares of the company’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $71.52, for a total value of $786,720.00. Following the transaction, the insider now directly owns 15,206 shares in the company, valued at $1,087,533.12. The disclosure for this sale can be found here. Insiders have sold a total of 2,467,803 shares of company stock worth $182,590,696 over the last ninety days. 2.60% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in AMED. SG Americas Securities LLC acquired a new position in Amedisys during the 1st quarter valued at about $123,000. LS Investment Advisors LLC increased its position in Amedisys by 233.1% during the 4th quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock valued at $188,000 after buying an additional 2,494 shares in the last quarter. Xact Kapitalforvaltning AB acquired a new position in Amedisys during the 1st quarter valued at about $257,000. Paloma Partners Management Co acquired a new position in shares of Amedisys in the fourth quarter valued at about $310,000. Finally, Stone Ridge Asset Management LLC acquired a new position in shares of Amedisys in the fourth quarter valued at about $364,000. 93.85% of the stock is currently owned by institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.